Thank you! Your request has been received.
A member of our team will reach out to you shortly,
Oops! Something went wrong while submitting the form.
+
Pienomial’s Knolens is an AI-powered pharmaceutical intelligence platform unifying scientific, regulatory, and clinical data into real-time, traceable insights. Founded in 2020, it supports Clinical, HEOR, and Market Access teams at biotech and pharma companies across Boston, New Jersey, and global hubs.
Knolens helps pharma companies model market access with real-time HTA data, track global reimbursement, and accelerate payer submissions. By strengthening evidence-based value narratives, Boston and New Jersey teams cut time-to-reimbursement 50–70% across US, European, and global markets with AI-powered intelligence.
Knolens helps clinical teams optimize trial design with AI scenario modeling of criteria, endpoints, and populations. By analyzing FDA/EMA study data, it delivers feasibility insights and protocol recommendations, enabling 40–60% faster trial startups and higher success rates through precedent-based optimization.
Knolens gives regulatory teams scenario-based insights on FDA labels, EMA pathways, and endpoint changes. It tracks global precedents, delivers AI-curated evidence, and enables faster responses. Regulatory affairs teams cut submission prep time 60% while boosting approval probability through optimized strategies.
Knolens enables CI teams to simulate market shifts, track pipelines, and run AI-driven scenarios. It anticipates competitor moves, detects early signals, and provides downstream impact analysis, giving pharma companies a 3–6 month competitive edge with predictive modeling.
Knolens supports strategy teams by simulating integrated clinical, regulatory, and market strategies with real-world pharma data. It tracks endpoints, derisks go/no-go decisions, and aligns development with market access, reducing late-stage failures by 30–40% through AI-driven strategy modeling.
Knolens empowers executives with real-time business scenario modeling by combining internal pharma data and market intelligence. It delivers defensible AI insights for strategic planning, helping C-suites optimize portfolio decisions, market entry timing, and resource allocation across therapeutic areas with predictive intelligence.
Knolens empowers cross-functional teams across Clinical, HEOR, Market Access and more to execute real-time, traceable analyses—modeling endpoints, comparing study designs, and running scenario-based simulations using continuously updated, regulatory-grade data that is 100% traceable.
We've covered most of the common questions below.
Knolens serves biotech companies and pharmaceutical firms across major life sciences hubs including Boston's biotech corridor, New Jersey's pharmaceutical cluster, and European pharma centers. Client companies range from early-stage biotech startups to global pharmaceutical corporations.
Knolens maintains >95% accuracy in data analysis and literature extraction, with full source traceability meeting FDA and EMA regulatory requirements for evidence-based submissions.
Knolens covers 100+ medical indications across oncology, rare diseases, immunology, neurology, and other therapeutic areas commonly developed by pharmaceutical companies.
Unlike legacy database platforms, Knolens provides real-time AI-powered analysis with natural language querying, reducing pharmaceutical intelligence gathering time by over 80% compared to manual methods.
Yes, Knolens scales from Cambridge biotech startups to global pharmaceutical corporations, adapting to company size and specific pharmaceutical intelligence needs.
